Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Trial Profile

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Interferon; Thalidomide
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 21 Sep 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 08 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top